OnKure Therapeutics, Inc. (OKUR)
NASDAQ: OKUR · Real-Time Price · USD
17.03
-0.15 (-0.87%)
Oct 25, 2024, 4:00 PM EDT - Market closed
Company Description
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.
The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors.
The company was incorporated in 2011 and is based in Boulder, Colorado.
OnKure Therapeutics, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Nicholas Saccomano |
Contact Details
Address: 6707 Winchester Circle, Suite 400 Boulder, Colorado 80301 United States | |
| Phone | 720 307 2892 |
| Website | onkuretherapeutics.com |
Stock Details
| Ticker Symbol | OKUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001637715 |
| ISIN Number | US68277Q1058 |
| Employer ID | 47-2309515 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anthony D. Piscopio Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Jason A. Leverone CPA | Chief Financial Officer |
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer |
| Rogan P. Nunn | General Counsel and Secretary |
| Prof. Xuedong Liu Ph.D. | Member of Scientific Advisory Board |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery |
| Dr. Richard Woessner Ph.D. | Senior Vice President of Pharmacology |
| Dr. Duncan Walker Ph.D. | Chief Development Officer |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK and Clinical Pharmacology |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 21, 2024 | D | Notice of Exempt Offering of Securities |
| Oct 16, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |